<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug Application for SULFAMYLON® (Mafenide Acetate, USP) Powder for 5% Topical Solution</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <style>
        body { font-family: Arial, sans-serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { color: #333; }
        .metadata { color: #666; font-size: 0.9em; }
        .summary { margin-top: 20px; line-height: 1.5; }
        .source { margin-top: 20px; }
    </style>
</head>
<body>
    <h1>Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug Application for SULFAMYLON® (Mafenide Acetate, USP) Powder for 5% Topical Solution</h1>
    <div class="metadata">Published: 2026-02-05 12:26:21</div>
    <div class="summary">The Food and Drug Administration (FDA) is withdrawing approval of new drug application (NDA) 019832 for SULFAMYLON[supreg] (Mafenide Acetate, USP) Powder for 5% Topical Solution, held by Mylan Institutional, Inc., a Viatris company (Mylan). Mylan has voluntarily requested withdrawal of this application and has waived its opportunity for a hearing.</div>
    <div class="source">Source: <a href="https://www.federalregister.gov/documents/2022/11/30/2022-26057/mylan-institutional-inc-withdrawal-of-approval-of-a-new-drug-application-for-sulfamylon-mafenide" target="_blank" rel="noopener noreferrer">https://www.federalregister.gov/documents/2022/11/30/2022-26057/mylan-institutional-inc-withdrawal-of-approval-of-a-new-drug-application-for-sulfamylon-mafenide</a></div>
</body>
</html>
